Trikafta Five-Year Data Shows Sustained Lung Function in CF

WHY IT MATTERS

Confirms Trikafta as transformative long-term CF therapy. 90% of CF patients now have a modulator.

Long-term data shows sustained improvement in lung function over five years in cystic fibrosis patients with at least one F508del mutation.

Related conditions